ArticleFrontiers in medicine2025
Successful treatment of pityriasis lichenoides et varioliformis acuta with stapokibart: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pityriasis lichenoides et varioliformis acuta (PLEVA) is a relatively rare inflammatory skin disorder encountered in clinical practice. Stapokibart is a humanized monoclonal antibody drug targeting the interleukin receptor subunit α (IL-4Rα), and is primarily used for the treatment of atopic dermatitis. Currently, owing to the rarity of PLEVA in clinical practice, there have been no reports on the use of Stapokibart in its treatment. This article presents a case in which stapokibart was used to treat a patient with acute acneiform lichenoid pityriasis, demonstrating its clinical efficacy. Following treatment with biological agents, the patient's rash completely resolved, and their quality of life significantly improved, without any adverse reactions. This case provides a valuable reference for the clinical treatment of PLEVA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.